These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9267751)

  • 1. Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen.
    Studer-Sachsenberg EM; Piletta PA; Fathi M; Saurat JH; Salomon D
    Dermatology; 1997; 195(1):81-3. PubMed ID: 9267751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Influence of retinoids on the bioavailability of methoxy-8-psoralen].
    Beani JC; Bonnot D; Berthod F; Boitard M; Reymond JL; Beriel H; Amblard P
    Ann Dermatol Venereol; 1991; 118(4):273-5. PubMed ID: 2069337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High plasma levels of 8-methoxypsoralen following bath water delivery in dermatological patients.
    Kappes UP; Barta U; Merkel U; Balogh A; Elsner P
    Skin Pharmacol Appl Skin Physiol; 2003; 16(5):305-12. PubMed ID: 12907835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of 8-methoxypsoralen during extracorporeal photopheresis.
    Shephard SE; Nestle FO; Panizzon R
    Photodermatol Photoimmunol Photomed; 1999 Apr; 15(2):64-74. PubMed ID: 10321518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spectrofluorimetric determination of 5-methoxypsoralen pharmacokinetic in patients' serum.
    Saïd A; Makki S; Muret P; Toubin G; Humbert P; Millet J
    Exp Dermatol; 1997 Apr; 6(2):57-63. PubMed ID: 9209885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Determination of 8-methoxypsoralen in mouse plasma by high performance liquid chromatography and its application to pharmacokinetic study].
    Wu TW; Cui R; Zhang BX
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Oct; 50(5):792-796. PubMed ID: 30337737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phototesting in bath-PUVA: marked reduction of 8-methoxypsoralen (8-MOP) activity within one hour after an 8-MOP bath.
    Schempp CM; Schöpf E; Simon JC
    Photodermatol Photoimmunol Photomed; 1996 Jun; 12(3):100-2. PubMed ID: 8956358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug monitoring of orally administered 8-methoxypsoralen in patients treated with extracorporeal photopheresis.
    Balogh A; Merkel U; Looks A; Vollandt R; Wollina U
    Skin Pharmacol Appl Skin Physiol; 1998; 11(4-5):258-65. PubMed ID: 9885410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic behaviour of sublingually administered 8-methoxypsoralen for PUVA therapy.
    Shephard SE; Langguth P; Panizzon RG
    Photodermatol Photoimmunol Photomed; 2001 Feb; 17(1):11-21. PubMed ID: 11169171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial distribution of 8-methoxypsoralen penetration into human skin after systemic or topical administration.
    Grundmann-Kollmann M; Podda M; Bräutigam L; Hardt-Weinelt K; Ludwig RJ; Geisslinger G; Kaufmann R; Tegeder I
    Br J Clin Pharmacol; 2002 Nov; 54(5):535-9. PubMed ID: 12445034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetic comparison of 3 8-methoxypsoralen preparations and clinical aspects].
    Walther T; Haustein UF; Quednow B; Meyer FP
    Hautarzt; 1990 Jun; 41(6):317-21. PubMed ID: 2380068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of 8-methoxypsoralen after bath-PUVA for psoriasis: relationship to disease severity.
    Gómez MI; Azaña JM; Arranz I; Harto A; Ledo A
    Br J Dermatol; 1995 Jul; 133(1):37-40. PubMed ID: 7669638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of 8-methoxypsoralen during extracorporeal photochemotherapy: evidence for a "first-dose" effect.
    Jacolot A; Tod M; Heudes AM; Petitjean O; Laroche L
    Ther Drug Monit; 1996 Jun; 18(3):234-9. PubMed ID: 8738761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calculation of 8-methoxypsoralen dose according to body surface area in PUVA treatment.
    Sakuntabhai A; Diffey BL; Farr PM
    Br J Dermatol; 1995 Dec; 133(6):919-23. PubMed ID: 8547045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronopharmacokinetics of 5-methoxypsoralen.
    Treffel P; Renaud A; Humbert P; Makki S; Faivre B; Agache PG
    Acta Derm Venereol; 1990; 70(6):515-7. PubMed ID: 1981428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bath PUVA--an investigation of the distribution of trioxsalen (TMP) and 8-methoxypsoralen (8-MOP) in bathwater.
    Wainwright NJ; MacLeod TM; Ferguson J
    Photodermatol Photoimmunol Photomed; 1997; 13(1-2):17-20. PubMed ID: 9361123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy.
    Shephard SE; Panizzon RG
    Dermatology; 1999; 199(2):106-12. PubMed ID: 10559574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time course of 8-methoxypsoralen concentrations in skin and plasma after topical (bath and cream) and oral administration of 8-methoxypsoralen.
    Tegeder I; Bräutigam L; Podda M; Meier S; Kaufmann R; Geisslinger G; Grundmann-Kollmann M
    Clin Pharmacol Ther; 2002 Mar; 71(3):153-61. PubMed ID: 11907489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
    Tanew A; Ortel B; Rappersberger K; Hönigsmann H
    J Am Acad Dermatol; 1988 Feb; 18(2 Pt 1):333-8. PubMed ID: 3279089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
    Berg M; Ros AM
    Photodermatol Photoimmunol Photomed; 1994 Oct; 10(5):217-20. PubMed ID: 7880762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.